CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Purchased by Hennion & Walsh Asset Management Inc.

Hennion & Walsh Asset Management Inc. raised its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) by 9.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 44,305 shares of the company’s stock after acquiring an additional 3,737 shares during the period. Hennion & Walsh Asset Management Inc. owned approximately 0.05% of CRISPR Therapeutics worth $1,744,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. Baker BROS. Advisors LP lifted its position in CRISPR Therapeutics by 743.1% during the third quarter. Baker BROS. Advisors LP now owns 843,075 shares of the company’s stock worth $39,608,000 after buying an additional 743,075 shares in the last quarter. State Street Corp raised its holdings in shares of CRISPR Therapeutics by 25.0% during the 3rd quarter. State Street Corp now owns 2,992,988 shares of the company’s stock worth $140,611,000 after acquiring an additional 599,304 shares during the period. Farallon Capital Management LLC purchased a new stake in shares of CRISPR Therapeutics in the second quarter valued at about $28,625,000. Marshall Wace LLP acquired a new stake in CRISPR Therapeutics during the second quarter worth about $10,078,000. Finally, Granite Bay Wealth Management LLC purchased a new position in CRISPR Therapeutics during the second quarter worth about $2,375,000. 69.20% of the stock is owned by hedge funds and other institutional investors.

CRISPR Therapeutics Price Performance

CRSP stock opened at $40.53 on Friday. CRISPR Therapeutics AG has a 1 year low of $36.52 and a 1 year high of $91.10. The firm has a market capitalization of $3.46 billion, a P/E ratio of -14.32 and a beta of 1.68. The business’s 50-day moving average is $45.01 and its two-hundred day moving average is $48.16.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.42) by $0.41. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. The company had revenue of $0.60 million during the quarter, compared to the consensus estimate of $6.65 million. During the same quarter in the previous year, the firm earned ($1.41) earnings per share. On average, analysts expect that CRISPR Therapeutics AG will post -5.13 EPS for the current year.

Insider Buying and Selling

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 15,000 shares of the firm’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $55.10, for a total value of $826,500.00. Following the sale, the chief executive officer now directly owns 181,540 shares in the company, valued at $10,002,854. This trade represents a 7.63 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 4.10% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently weighed in on CRSP. StockNews.com raised shares of CRISPR Therapeutics to a “sell” rating in a research note on Monday, December 30th. Bank of America cut their target price on CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. Needham & Company LLC reaffirmed a “buy” rating and issued a $84.00 price target on shares of CRISPR Therapeutics in a research note on Tuesday. JMP Securities reissued a “market outperform” rating and set a $86.00 price objective on shares of CRISPR Therapeutics in a research report on Friday, December 20th. Finally, Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $53.00 target price on shares of CRISPR Therapeutics in a research report on Wednesday, November 6th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and ten have assigned a buy rating to the company’s stock. According to data from MarketBeat, CRISPR Therapeutics currently has an average rating of “Hold” and an average price target of $78.38.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.